Table 3 Appraisal of Guidelines Research and Evaluation of the guidelines
Appraisal of Guidelines Research and Evaluation criterion | EULAR [6] | Ottawa Panel [11] | ICSI [9] | CCC [8] | AAOS [10] | Schnitzer/ACR [7] |
|---|---|---|---|---|---|---|
Scope/purpose | ||||||
1. Overall objective(s) specifically described | 2 | 3 | 2 | 3 | 3 | 3 |
2. Clinical question(s) specifically described | 3 | 2 | 4 | 2 | 2 | 3 |
3. Patients to whom the guideline is meant to apply specifically described | 3 | 4 | 4 | 2 | 3 | 2 |
Stakeholder involvement | ||||||
4. Development group included individuals from all relevant professional groups | 2 | 4 | 2 | 4 | 1 | 1 |
5. Patients' views and preferences sought | 1 | 2 | 1 | 4 | 1 | 2 |
6. Target users clearly defined | 1 | 4 | 4 | 1 | 4 | 1 |
7. Guideline piloted among end users | 1 | 1 | 1 | 1 | 1 | 1 |
Rigour of development | ||||||
8. Systematic methods used to search for evidence | 3 | 3 | 1 | 3 | 2 | 1 |
9. Criteria for selecting evidence clearly described | 4 | 4 | 1 | 2 | 1 | 2 |
10. Methods used for formulating the recommendations clearly described | 3 | 2 | 1 | 1 | 3 | 1 |
11. Health benefits, side effects and risks considered in formulating the recommendations | 4 | 3 | 2 | 4 | 2 | 4 |
12. Explicit link between recommendations and supporting evidence | 4 | 4 | 3 | 4 | 2 | 3 |
13. Guideline externally reviewed by experts prior to publication | 1 | 3 | 1 | 1 | 2 | 1 |
14. Procedure for updating the guideline provided | 1 | 1 | 3 | 3 | 2 | 1 |
Clarity/presentation | ||||||
15. Specific and unambiguous recommendations | 3 | 2 | 3 | 2 | 2 | 1 |
16. Different options for diagnosis and/or treatment of the condition clearly presented | 3 | 4 | 3 | 4 | 2 | 3 |
17. Key recommendations easily identifiable | 4 | 3 | 4 | 4 | 4 | 1 |
18. Guideline supported with tools for application | 2 | 2 | 4 | 2 | 2 | 1 |
Applicability | ||||||
19. Potential organizational barriers in applying the recommendations discussed | 1 | 2 | 2 | 1 | 1 | 1 |
20. Potential cost implications of applying the recommendations considered | 1 | 1 | 1 | 4 | 1 | 2 |
21. Guideline presents key review criteria for monitoring and audit purposes | 1 | 1 | 3 | 1 | 1 | 1 |
Editorial independence | ||||||
22. Guideline editorially independent from the funding body | 3 | 3 | 1 | 4 | 1 | 1 |
23. Conflicts of interest of guideline development members recorded | 1 | 1 | 4 | 4 | 1 | 4 |